Palbociclib + fulvestrant in a positive hormonal receptors metastatic breast cancer

Palbocilcib is a first-in-class drug, that demonstrated in several studies, improvements in progression-free-survival, in combination with endocrine therapy. Palbociclib with fulvestrant improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer. The author reports the case of a 63-year-old metastatic breast cancer patient, positive for hormonal receptors, that had received multiple chemotherapy regimens. She was treated with palbociclib plus fulvestrant. Three months later she obtained partial response. However she also experienced side-effects such as grade IV neutropenia and grade III thrombopenia, that led to palbociclib reduction.

Palbociclib; Fulvestrant; Metastases; breast cancer; Positive hormonal receptors; Neutropenia; thrombopenia

[1] Nicholson R.I., Hutcheson I.R., Jones H.E., Hiscox S.E., Giles M., Taylor K.M., Gee J.M.: “Growth factor signalling in endocrine and anti-growth factor resistant breast cancer”. Rev. Endocr. Metab. Disord., 2007, 8, 241.

[2] Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., et al.: “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro”. Breast Cancer Res., 2009, 11, R77

[3] Finn R.S., Crown J.P., Lang I., et al.: “Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC)”. Cancer Res., 2012, 72, Abstract nr S1.

[4] Finn R.S., Martin M., Rugo H.S., Jones S.E., Im S-A., et al.: “PALOMA-2: Primary results from a phase III trial of palbociclib

(P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC)”. J Clin Oncol. 2016, 34, abstract 507.

[5] Cristofanilli M., Turner N., Bondarenko I., Ro J., Im S.A., Masuda N., et al.: “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 2016, 17, 425.